Sara Tolaney

Oct 9, 2024, 14:00 | Blog

Oncoinfluencers to Follow on Social Media: Dr. Sara Tolaney

We are excited to introduce Dr. Sara Tolaney, a leading expert in breast oncology, as…

Oct 6, 2024, 07:42 | Positive

100 Influential Women in Oncology: Key Opinion Leaders to Follow on Social Media in 2024: Part 6

This week, we continue featuring 100 influential women in oncology, and here is the list…

Sep 20, 2024, 13:00 | Blog

The 1st webinar of the ’24-‘25 EMBRACE Metastatic Breast Cancer Forum Series - Dana-Farber Cancer Institute

Dana-Farber Cancer Institute shared a post on X: ''Join Nancy Lin, and Sara Tolaney, via Zoom for…

Sep 18, 2024, 23:03 | Insight

Aleix Prat: Dual HER2 inhibition in Breast Cancer

Aleix Prat shared a post on X about a recent paper by Adrienne Waks et…

Sep 10, 2024, 10:45 | Blog

Sara Tolaney: Mark your calendars for PER’s School of Breast Oncology

Sara Tolaney shared a post on X: “Mark your calendars for PER’s School of Breast…

Sep 7, 2024, 19:36 | Insight

A year of treatment with an ADC has proven highly effective in preventing stage 1 HER2-positive breast cancer from recurring - Dana-Farber Cancer Institute

Dana-Farber Cancer Institute shared the following on LinkedIn: “A year of treatment with a medicine…

Sep 6, 2024, 11:25 | Insight

Paolo Tarantino: Interesting RWA of outcomes with chemotherapy in HR+/HER2- MBC

Paolo Tarantino shared a post by ESMO Open on X, adding: "Interesting real world analysis…

Sep 1, 2024, 15:26 | Insight

Guillermo Villacampa: Meta-analysis evaluating immunotherapy in early breast cancer

Recently, an article by Guillermo Villacampa et al. was published in JAMA Oncology. "Neoadjuvant Immune…

Jul 26, 2024, 00:18 | Blog

Sara Tolaney on novel therapies for young women with breast cancer at Young Women's Forum

Young Women's Forum shared on X: "Honored to have Sara Tolaney, Chief of Breast Oncology…

Jul 25, 2024, 08:58 | Insight

Marleen Kok: How do we get from one-size-fits-all to personalized treatment for TNBC

Marleen Kok, Breast Medical Oncologist at the Netherlands Cancer Institute, shared on X: "Today from…

Jul 14, 2024, 21:42 | Blog

Paolo Tarantino: Stellar Tumor Board session at the Harvard Medical School Breast Course

Paolo Tarantino shared a post on X: ''Stellar Tumor Board session at the Harvard Medical…

Jul 12, 2024, 20:47 | Societies

Stuart Schnitt on the future of breast pathology with the potential benefits of AI

Sara Tolaney shared on X: "Dr Stuart Schnitt does an outstanding job highlighting the future…

Jul 5, 2024, 05:41 | Blog

Abeid Athman: Joining ASCO had a huge role in shaping my career

Abeid Athman, Clinical Oncologist at Kenyatta University Hospital, shared on X: "It has been 5…

Jul 3, 2024, 22:59 | Blog

Aleix Prat: Our 2 articles published this week

Aleix Prat, Head of the Medical Oncology Department at Hospital Clínic Barcelona, shared on X:…

Jul 3, 2024, 10:44 | Blog

Abeid M. Athman Omar: The last four months have been very eventful for me

Abeid M. Athman Omar, Clinical Oncology Specialist at Kenyatta University, shared a post on LinkedIn: "The last…

Jul 3, 2024, 01:24 | Blog

Paolo Tarantino: ATEMPT would have not been possible without the vision of Sara Tolaney

Sara Tolaney shared a post by Paolo Tarantino on X: “Very lucky to get to…

Jul 2, 2024, 10:32 | Insight

Trastuzumab emtansine (T-DM1) is highly effective in preventing stage 1 HER2-positive breast cancer from recurring - MedEdge MEA

MedEdge MEA shared a post on LinkedIn: . "A year of treatment with a medicine…

Jul 1, 2024, 15:23 | Insight

Paolo Tarantino: Final analysis of the ATEMPT phase 2 trial

Paolo Tarantino shared a post on X: “Can ADCs help prevent recurrence from breast cancer…

Jun 26, 2024, 03:41 | Insight

Paolo Tarantino: Opportunities to improve outcomes for early recurrent TNBC

Paolo Tarantino shared a post on X: . "Early recurrent TNBC (Triple-Negative…

Jun 22, 2024, 04:43 | Blog

Sara Tolaney: Please consider attending the School of Breast Oncology

Hope Rugo, Medical hematologist-oncologist at UCSF, shared a post by Sara Tolaney, on X: ''It is indeed.…

Jun 11, 2024, 15:21 | Blog

Abeid M. Athman Omar: Delighted to have received two awards at the ASCO24 meeting

Abeid M. Athman Omar, Clinical Oncology Specialist at Kenyatta University, shared a post on LinkedIn: ''I am…

May 31, 2024, 18:51 | Blog

Sameh Abdelmalak: Dr. Sara Tolaney and Dr. Hope Rugo discussing ASCO24 Noteworthy Abstracts in Breast Cancer

Sameh Abdelmalak, Director, Oncology, Educational Partnerships at VuMedi, made the following post on X: "Check…

May 22, 2024, 08:48 | Blog

SITC will host the free Summit on Immunomodulation of ADCs

Society for Immunotherapy of Cancer shared a post on X: “SITC will host the free Summit…

May 20, 2024, 13:16 | Career

Sara Tolaney is appointed as Alliance for Clinical Trials in Oncology Breast Committee Vice-Chair

Alliance for Clinical Trials in Oncology recently shared on X: "Congratulations to Sara Tolaney, MD,…

May 18, 2024, 10:02 | Societies

Matteo Lambertini: What a big honor to have Sara Tolaney at our ESMOYOC session

Matteo Lambertini, Medical Oncologist at San Martino, shared on X: . "What a big honor…

May 18, 2024, 09:54 | Societies

Paolo Tarantino: Why was IMpassion132 negative?

Daniel Stover, Medical Oncologist and Computational Biologist at Ohio State University Comprehensive Cancer Center, shared…

May 18, 2024, 08:12 | Blog

Paolo Tarantino: Sara Tolaney recapitulating 10+ years of de-escalation trials

Paolo Tarantino shared a post on X/Twitter: ''Terrific presentation by Sara Tolaney at ESMO Breast24, recapitulating…

May 18, 2024, 04:17 | Blog

Sara Tolaney: Interesting data from Mafalda Oliveira from SERENA-2 at ESMO Breast24

Sara Tolaney shared a post on X: ''Interesting data from Mafalda Oliveira from SERENA-2 demonstrating…

May 17, 2024, 11:41 | Insight

Sara Tolaney: Helpful discussion by Cristina Saura on how to think about adjuvant therapies in patients with gBRCAm

Sara Tolaney shared a post on X: “Very helpful discussion by Cristina Saura on how…

May 14, 2024, 16:00 | Blog

Dr. Sara Tolaney will be the invited discussant for three excellent Breast Cancer trials at ESMO Breast 24 - Dana Farber’s Breast Oncology Center

Dana Farber’s Breast Oncology Center shared a post on X: “Check out the ESMO Breast 24…

May 7, 2024, 11:51 | Positive

Sara Tolaney: HAPPY NURSES WEEK!

Sara Tolaney shared a post on X: "HAPPY NURSES WEEK! A special thank you to…

May 7, 2024, 03:53 | Blog

Aleix Prat: Dr. Tomás Pascual, will be co-presenting an educational talk alongside Sara Tolaney and Tatiana Prowell

Aleix Prat, Director of the Oncology Institute at Hospital Clínic Barcelona, shared a post on X:…

May 5, 2024, 06:21 | Blog

Sara Tolaney discussed the new breast cancer screening guidelines - Dana-Farber’s Breast Oncology Center

Dana-Farber’s Breast Oncology Center shared on their X/Twitter: ''Sara Tolaney discussed the new breast cancer…

May 1, 2024, 13:41 | Opinion

Sara Tolaney: Such an important question addressed in the Alliance A011502 study

Sara Tolaney shared a post by Erman Akkus, Medical Oncology Fellow at Ankara University, on X/Twitter: "Such…

Apr 22, 2024, 11:40 | Blog

Sara Tolaney: Very excited to have Aleix Prat as the Schlager Lecturer at the Harvard Breast Course in July!

Sara Tolaney shared a post by Aleix Prat, Co-Founder of Reveal Genomics, on X/Twitter, adding:…

Mar 24, 2024, 08:23 | Drugs

Paolo Tarantino: Adding palbociclib to fulvestrant did not improve PFS in the PACE randomized phase 2 trial

Paolo Tarantino, Medical Oncologist and Research Fellow at Dana-Farber Cancer Institute, shared a post on…

Feb 27, 2024, 15:28 | Blog

Dr. Sara Tolaney discusses Antibody Drug Conjugates - Dana-Farber’s Breast Oncology Center

Quoting Dana-Farber’s Breast Oncology Center on X/Twitter: "Dr. Sara Tolaney discusses Antibody Drug Conjugates in…

Feb 14, 2024, 13:13 | Blog

Chiara Corti: Thanks so much to Gianni Bonadonna Foundation and AIRC Foundation for cancer research for this opportunity

Chiara Corti, Research Fellow at Dana-Farber Cancer Institute, shared a post by Gianni Bonadonna Foundation…

Dec 17, 2023, 17:26 | Blog

25 Posts Not To Miss From SABCS 2023

The San Antonio Breast Cancer Symposium 2023 (SABCS 2023) took place in San Antonio, Texas…

Dec 8, 2023, 17:54 | Career

Dana-Farber News congratulates Sara Tolaney on receiving the Susan G. Komen 2023 Rising Star Researcher Award

Dana-Farber News /Dana Farber Cancer Institute/ shared on their X/Twitter account: "Congrats to Dana-Farber Cancer…

Nov 1, 2023, 18:54 | Societies

20 Posts Not To Miss From ESMO 2023 Congress

The Annual Congress of the European Society For Medical Oncology (ESMO) took place from October…

Oct 21, 2023, 21:40 | Positive

100 Influential Women in Oncology: Key Opinion Leaders to follow on Social Media in 2023: Part 9

We continue OncoDaily’s ‘100 Influential Women in Oncology: Key Opinion Leaders to Follow on Social…

Oct 13, 2023, 17:39 | Blog

Sara Tolaney: Consider applying to the Gilead Research Scholars program if you are a junior faculty member looking for funding for research in solid tumors!

Quoting Sara Tolaney, Chief of the Division of Breast Oncology at Dana-Farber Cancer Institute, on…

Sep 15, 2023, 18:51 | Blog

Michail Ignatiadis: Join us tomorrow with ⁦Peter Fasching, Sara Tolaney and Stephen Johnston to discuss QoL in the phase 3 NATALEE trial of adjuvant ribociclib

Quoting Michail Ignatiadis, Director of Breast Medical Oncology Clinic & Program, Jules Bordet Institute, on…

Aug 25, 2023, 18:26 | Insight

Sara Tolaney: TROPICS-02 Overall Survival data now published in The Lancet!

Quoting Sara Tolaney, Chief of Division of Breast Oncology at Dana Farber Cancer Institute, on…

Aug 14, 2023, 17:39 | Insight

Check out the new review just published in Cancers MDPI on Tumor Mutational Burden in Breast Cancer - Dana-Farber’s Breast Oncology Center

Quoting from a recent tweet by Dana-Farber’s Breast Oncology Center: "Check out the new review…

All: 46 Posts: 1 - 100